Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on May 8, 2023, at 4:30 PM ET to discuss a business update and report first quarter 2023 financial results. Investors can join the call by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (international) and using passcode 2096044. A live webcast will also be available through the investor relations section on the Corvus website.

Corvus Pharmaceuticals is focused on developing novel therapies for cancer. Its lead candidate, CPI-818, is in a Phase 1/1b trial aimed at T cell lymphomas, while two additional programs, CPI-444 and CPI-006, are also in various stages of clinical trials. The company continues to advance its innovative pipeline in the biopharma sector.

Corvus Pharmaceuticals (Nasdaq: CRVS) has announced promising preclinical data for its investigational drug CPI-818, an ITK inhibitor aimed at treating various cancers. The data, presented at the AACR Annual Meeting, indicates CPI-818 effectively inhibits tumor growth in models of colon, renal, and melanoma cancers, as well as T and B cell lymphomas. The mechanism of action involves enhancing T cell differentiation and reducing T cell exhaustion, potentially positioning CPI-818 for broad cancer immunotherapy applications. The company is currently enrolling patients in a Phase 1/1b trial focusing on T cell lymphoma and plans to meet with the FDA to discuss a Phase 3 trial. Corvus anticipates presenting updated clinical trial data in the second quarter of 2023.

Corvus Pharmaceuticals (Nasdaq: CRVS) recently presented interim data from its Phase 1/1b clinical trial of CPI-818 for T cell lymphoma at the Whistler Global Summit on Hematologic Malignancies. The data, revealed by Dr. John Reneau, indicates promising results with CPI-818 demonstrating monotherapy activity in relapsed patients. Key findings include one complete response lasting 24 months and an overall median progression-free survival (PFS) of 28.1 months for patients with an absolute lymphocyte count (ALC) above 900. Corvus aims to leverage this biomarker for patient enrollment in future trials.

Corvus Pharmaceuticals (CRVS) announced a business update and 2022 financial results on March 28, 2023. The company reported a cash balance of $42.3 million. The focus remains on CPI-818, an ITK inhibitor for T cell lymphoma, which has shown promising clinical data, with 20 patients enrolled in a Phase 1/1b trial. A predictive biomarker has been identified, indicating better tumor response rates with absolute lymphocyte counts above 900. The FDA has provided guidance for the next steps in clinical trials. Corvus also plans to pause CPI-818 development for atopic dermatitis to concentrate resources on cancer therapies.

Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on March 28, 2023, at 4:30 pm ET to present a business update and report its financial results for Q4 and full year 2022.

This session can be accessed through dial-in numbers provided or via a live webcast on the company's investor relations website. A replay will be available for 90 days post-call. Corvus is focused on developing innovative therapies, with its lead candidate, CPI-818, currently in a Phase 1/1b trial for T cell lymphomas. Other candidates include CPI-444 and CPI-006, which are in various stages of clinical trials.

Corvus Pharmaceuticals (Nasdaq: CRVS) announced new preclinical data for its drug CPI-818 during the ongoing Phase 1/1b clinical trial aimed at treating refractory T cell lymphoma. The data, to be presented at the AACR Annual Meeting from April 14-19, 2023, showcases CPI-818's anti-tumor activity in murine models, including complete tumor elimination in combination with anti-PD1 and anti-CTLA4 therapies. The findings suggest a broad potential for CPI-818 in solid tumors and indicate favorable immune responses, highlighting its role in enhancing tumor immunotherapy.